Johnson & Johnson MedTech (NYSE: JNJ) announced today that the FDA cleared its Monarch Quest technology for robotic-assisted ...

Johnson & Johnson MedTech said Wednesday its Monarch Quest robotic platform received clearance from the Food and Drug ...

Two companies have received approved for a generic of the 2.5 mg tablet of anticoagulant rivaroxaban, which is used to reduce ...

Analysts say the decision is a “big blow” to a once-promising class of brain therapies that include’s J&J’s aticaprant and a ...

A depression drug candidate that’s a key part of Johnson & Johnson’s neuroscience strategy has failed a Phase 3 clinical trial, the latest dose of disappointing news for an emerging class of ...

Johnson & Johnson MedTech (NYSE: JNJ) announced new regulatory nods for multiple orthopedic technology offerings.

The latest health news includes Johnson & Johnson halting testing on a depression drug, USDA eliminating food safety advisory ...

JNJ's $14B acquisition of ITCI bolsters its portfolio with Caplyta, showing strong sales and patent protection until 2033.

Johnson & Johnson (NYSE:JNJ) recently announced the appointment of Jessica Moore as the Group Chief Financial Officer for ...